Abstract
The novel ribonuclease inhibitor LoRI is a 63 kDa recombinant protein optimized for high-throughput expression in E. coli and purification by metal chelate affinity chromatography (IMAC). The product was obtained by N-terminal fusion of mouse placental RNase inhibitor polypeptide to a thioredoxin module. Advantage of the engineering strategy in terms of protein structure and function was predicted in silico. Under laboratory settings, the yield of purified soluble recombinant product was about 12 mg per 1 L of expression bacterial culture. By RNase inhibition capacity in vitro, the product is comparable or superior to a commercial reference. The kinetic data comply with Lineweaver-Burk model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
